The Nigerian government has reduced the cost of dialysis for kidney patients from N50,000 to N12,000 per session at federal ...

Bristol Myers leans on new launches to offset legacy drug declines, while GSK's diverse portfolio and strong HIV lineup keep growth on track.

A federal judge tripled damages against the pharmacy benefits manager after finding it encouraged inflated Medicare drug ...

Wes Streeting has walked away from talks with pharmaceutical giants on NHS drug costs amid a stand-off over rebates.

A Lancaster firm is ‘incredibly proud’ to have received two separate major national plaudits.ICS Accounting, based on Caton Road, has been placed in the top 25 of the Financial Times’ top 500 UK’s ...

The pharmaceutical drug delivery market is entering a transformative phase, projected to grow from USD 1,949.4 billion in ...

Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's ...

Shares of Dynavax rose after the company released positive results from a trial of its shingles vaccine tested against current Shingles vaccine Shingrix. The stock was up 6.7% to $11.12 but is still ...

GSK paid $500 million upfront for global development rights to Hengrui’s portfolio of up to 12 early-stage assets. 2. Includes a PDE3/4 inhibitor for COPD plus programs in oncology, respiratory, ...

Dynavax (DVAX) stock gains as the company's Z-1018 shingles shot shows immune response comparable to GSK's (GSK) Shingrix vaccine in a Phase 1/2 trial. Read more here.

Dynavax’s lofty ambition to snatch Shingrix’s crown got off to a promising start after the biopharma’s investigational shingles vaccine held its own against GSK’s mainstay in the first part of a phase ...

On May 12, Trump signed an executive order stating that U.S. consumers are being overcharged for prescription drugs and that “Americans must therefore have access to the most-favored-nation price.” ...